Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease

Emanuele Barbato, Jozef Bartunek, Fabio Mangiacapra, Sebastiano Sciarretta, Rosita Stanzione, Leen Delrue, Maria Cotugno, Simona Marchitti, Guido Iaccarino, Giusy Sirico, Sara Di Castro, Anna Evangelista, Diether Lambrechts, Peter Sinnaeve, Bernard De Bruyne, Frans Van De Werf, Stefaan Janssens, Keith A A Fox, William Wijns, Massimo VolpeSperanza Rubattu

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives: The aim of this study was to investigate the impact of rs5065 atrial natriuretic peptide (ANP) gene variant on coronary artery disease (CAD) and its outcomes and to gain potential mechanistic insights on the association with CAD. Background: Either modified ANP plasma levels or peptide structural alterations have been involved in development of cardiovascular events. Methods: Three hundred ninety-three control subjects and 1,004 patients undergoing coronary angiography for suspected CAD (432 stable angina [SA], 572 acute coronary syndrome [ACS]) were genotyped for rs5065 ANP gene variant. Data in SA and ACS groups were replicated in an independent population of 482 stable angina patients (rSA) and of 675 ACS patients, respectively. Clinical follow-up was available for both SA and rSA patients. Plasma N-terminal-proANP, myeloperoxidase, lipoprotein-associated phospholipase A2, and oxidized low-density lipoprotein were assessed in a subgroup of rSA patients. Results: rs5065 minor allele (MA) was an independent predictor of ACS (odds ratio: 1.90; 95% confidence interval: 1.40 to 2.58, p <0.001). At follow-up, rs5065 MA was independently associated with a significantly higher rate of major adverse cardiovascular events in the SA group, p <0.001. Data were replicated in the rSA group at follow-up (p = 0.008). Cox proportional hazard analysis tested by 4 models confirmed higher major adverse cardiovascular events risk in rs5065 MA carriers in both SA and rSA cohorts. Significantly higher myeloperoxidase levels were detected in rs5065 MA carriers (n = 597 [345 to 832 μg/l] vs. n = 488 [353 to 612 μg/l], p = 0.038). No association of rs5065 was observed with N-terminal-proANP levels. Conclusions: The MA of rs5065 ANP gene variant associates with increased susceptibility to ACS and has unfavorable prognostic value in CAD.

Original languageEnglish
Pages (from-to)1763-1770
Number of pages8
JournalJournal of the American College of Cardiology
Volume59
Issue number20
DOIs
Publication statusPublished - May 15 2012

Fingerprint

Stable Angina
Atrial Natriuretic Factor
Acute Coronary Syndrome
Coronary Artery Disease
Alleles
Genes
Peroxidase
1-Alkyl-2-acetylglycerophosphocholine Esterase
Coronary Angiography
Odds Ratio
Confidence Intervals
Peptides
Population

Keywords

  • atrial natriuretic peptide
  • coronary artery disease
  • rs5065 gene variant

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. / Barbato, Emanuele; Bartunek, Jozef; Mangiacapra, Fabio; Sciarretta, Sebastiano; Stanzione, Rosita; Delrue, Leen; Cotugno, Maria; Marchitti, Simona; Iaccarino, Guido; Sirico, Giusy; Di Castro, Sara; Evangelista, Anna; Lambrechts, Diether; Sinnaeve, Peter; De Bruyne, Bernard; Van De Werf, Frans; Janssens, Stefaan; Fox, Keith A A; Wijns, William; Volpe, Massimo; Rubattu, Speranza.

In: Journal of the American College of Cardiology, Vol. 59, No. 20, 15.05.2012, p. 1763-1770.

Research output: Contribution to journalArticle

Barbato, E, Bartunek, J, Mangiacapra, F, Sciarretta, S, Stanzione, R, Delrue, L, Cotugno, M, Marchitti, S, Iaccarino, G, Sirico, G, Di Castro, S, Evangelista, A, Lambrechts, D, Sinnaeve, P, De Bruyne, B, Van De Werf, F, Janssens, S, Fox, KAA, Wijns, W, Volpe, M & Rubattu, S 2012, 'Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease', Journal of the American College of Cardiology, vol. 59, no. 20, pp. 1763-1770. https://doi.org/10.1016/j.jacc.2012.02.017
Barbato, Emanuele ; Bartunek, Jozef ; Mangiacapra, Fabio ; Sciarretta, Sebastiano ; Stanzione, Rosita ; Delrue, Leen ; Cotugno, Maria ; Marchitti, Simona ; Iaccarino, Guido ; Sirico, Giusy ; Di Castro, Sara ; Evangelista, Anna ; Lambrechts, Diether ; Sinnaeve, Peter ; De Bruyne, Bernard ; Van De Werf, Frans ; Janssens, Stefaan ; Fox, Keith A A ; Wijns, William ; Volpe, Massimo ; Rubattu, Speranza. / Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. In: Journal of the American College of Cardiology. 2012 ; Vol. 59, No. 20. pp. 1763-1770.
@article{8a5389d1f52a406284f87468e085af27,
title = "Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease",
abstract = "Objectives: The aim of this study was to investigate the impact of rs5065 atrial natriuretic peptide (ANP) gene variant on coronary artery disease (CAD) and its outcomes and to gain potential mechanistic insights on the association with CAD. Background: Either modified ANP plasma levels or peptide structural alterations have been involved in development of cardiovascular events. Methods: Three hundred ninety-three control subjects and 1,004 patients undergoing coronary angiography for suspected CAD (432 stable angina [SA], 572 acute coronary syndrome [ACS]) were genotyped for rs5065 ANP gene variant. Data in SA and ACS groups were replicated in an independent population of 482 stable angina patients (rSA) and of 675 ACS patients, respectively. Clinical follow-up was available for both SA and rSA patients. Plasma N-terminal-proANP, myeloperoxidase, lipoprotein-associated phospholipase A2, and oxidized low-density lipoprotein were assessed in a subgroup of rSA patients. Results: rs5065 minor allele (MA) was an independent predictor of ACS (odds ratio: 1.90; 95{\%} confidence interval: 1.40 to 2.58, p <0.001). At follow-up, rs5065 MA was independently associated with a significantly higher rate of major adverse cardiovascular events in the SA group, p <0.001. Data were replicated in the rSA group at follow-up (p = 0.008). Cox proportional hazard analysis tested by 4 models confirmed higher major adverse cardiovascular events risk in rs5065 MA carriers in both SA and rSA cohorts. Significantly higher myeloperoxidase levels were detected in rs5065 MA carriers (n = 597 [345 to 832 μg/l] vs. n = 488 [353 to 612 μg/l], p = 0.038). No association of rs5065 was observed with N-terminal-proANP levels. Conclusions: The MA of rs5065 ANP gene variant associates with increased susceptibility to ACS and has unfavorable prognostic value in CAD.",
keywords = "atrial natriuretic peptide, coronary artery disease, rs5065 gene variant",
author = "Emanuele Barbato and Jozef Bartunek and Fabio Mangiacapra and Sebastiano Sciarretta and Rosita Stanzione and Leen Delrue and Maria Cotugno and Simona Marchitti and Guido Iaccarino and Giusy Sirico and {Di Castro}, Sara and Anna Evangelista and Diether Lambrechts and Peter Sinnaeve and {De Bruyne}, Bernard and {Van De Werf}, Frans and Stefaan Janssens and Fox, {Keith A A} and William Wijns and Massimo Volpe and Speranza Rubattu",
year = "2012",
month = "5",
day = "15",
doi = "10.1016/j.jacc.2012.02.017",
language = "English",
volume = "59",
pages = "1763--1770",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "20",

}

TY - JOUR

T1 - Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease

AU - Barbato, Emanuele

AU - Bartunek, Jozef

AU - Mangiacapra, Fabio

AU - Sciarretta, Sebastiano

AU - Stanzione, Rosita

AU - Delrue, Leen

AU - Cotugno, Maria

AU - Marchitti, Simona

AU - Iaccarino, Guido

AU - Sirico, Giusy

AU - Di Castro, Sara

AU - Evangelista, Anna

AU - Lambrechts, Diether

AU - Sinnaeve, Peter

AU - De Bruyne, Bernard

AU - Van De Werf, Frans

AU - Janssens, Stefaan

AU - Fox, Keith A A

AU - Wijns, William

AU - Volpe, Massimo

AU - Rubattu, Speranza

PY - 2012/5/15

Y1 - 2012/5/15

N2 - Objectives: The aim of this study was to investigate the impact of rs5065 atrial natriuretic peptide (ANP) gene variant on coronary artery disease (CAD) and its outcomes and to gain potential mechanistic insights on the association with CAD. Background: Either modified ANP plasma levels or peptide structural alterations have been involved in development of cardiovascular events. Methods: Three hundred ninety-three control subjects and 1,004 patients undergoing coronary angiography for suspected CAD (432 stable angina [SA], 572 acute coronary syndrome [ACS]) were genotyped for rs5065 ANP gene variant. Data in SA and ACS groups were replicated in an independent population of 482 stable angina patients (rSA) and of 675 ACS patients, respectively. Clinical follow-up was available for both SA and rSA patients. Plasma N-terminal-proANP, myeloperoxidase, lipoprotein-associated phospholipase A2, and oxidized low-density lipoprotein were assessed in a subgroup of rSA patients. Results: rs5065 minor allele (MA) was an independent predictor of ACS (odds ratio: 1.90; 95% confidence interval: 1.40 to 2.58, p <0.001). At follow-up, rs5065 MA was independently associated with a significantly higher rate of major adverse cardiovascular events in the SA group, p <0.001. Data were replicated in the rSA group at follow-up (p = 0.008). Cox proportional hazard analysis tested by 4 models confirmed higher major adverse cardiovascular events risk in rs5065 MA carriers in both SA and rSA cohorts. Significantly higher myeloperoxidase levels were detected in rs5065 MA carriers (n = 597 [345 to 832 μg/l] vs. n = 488 [353 to 612 μg/l], p = 0.038). No association of rs5065 was observed with N-terminal-proANP levels. Conclusions: The MA of rs5065 ANP gene variant associates with increased susceptibility to ACS and has unfavorable prognostic value in CAD.

AB - Objectives: The aim of this study was to investigate the impact of rs5065 atrial natriuretic peptide (ANP) gene variant on coronary artery disease (CAD) and its outcomes and to gain potential mechanistic insights on the association with CAD. Background: Either modified ANP plasma levels or peptide structural alterations have been involved in development of cardiovascular events. Methods: Three hundred ninety-three control subjects and 1,004 patients undergoing coronary angiography for suspected CAD (432 stable angina [SA], 572 acute coronary syndrome [ACS]) were genotyped for rs5065 ANP gene variant. Data in SA and ACS groups were replicated in an independent population of 482 stable angina patients (rSA) and of 675 ACS patients, respectively. Clinical follow-up was available for both SA and rSA patients. Plasma N-terminal-proANP, myeloperoxidase, lipoprotein-associated phospholipase A2, and oxidized low-density lipoprotein were assessed in a subgroup of rSA patients. Results: rs5065 minor allele (MA) was an independent predictor of ACS (odds ratio: 1.90; 95% confidence interval: 1.40 to 2.58, p <0.001). At follow-up, rs5065 MA was independently associated with a significantly higher rate of major adverse cardiovascular events in the SA group, p <0.001. Data were replicated in the rSA group at follow-up (p = 0.008). Cox proportional hazard analysis tested by 4 models confirmed higher major adverse cardiovascular events risk in rs5065 MA carriers in both SA and rSA cohorts. Significantly higher myeloperoxidase levels were detected in rs5065 MA carriers (n = 597 [345 to 832 μg/l] vs. n = 488 [353 to 612 μg/l], p = 0.038). No association of rs5065 was observed with N-terminal-proANP levels. Conclusions: The MA of rs5065 ANP gene variant associates with increased susceptibility to ACS and has unfavorable prognostic value in CAD.

KW - atrial natriuretic peptide

KW - coronary artery disease

KW - rs5065 gene variant

UR - http://www.scopus.com/inward/record.url?scp=84860739086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860739086&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2012.02.017

DO - 10.1016/j.jacc.2012.02.017

M3 - Article

C2 - 22575314

AN - SCOPUS:84860739086

VL - 59

SP - 1763

EP - 1770

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 20

ER -